NR 511 Week 8 Final Exam
Document Preview
Unlock Full 15 Page Document Instantly.
Document Overview
3. You should treat it very aggressively, preferably with angiotensin-converting enzyme (ACE) inhibitors. 4. You should initiate therapy when the blood pressure is 5 to 10 mm Hg more than the conventional therapeutic guidelines. Rationales Option 1: Because hypertension is implicated in accelerating the microangiopathy of diabetes (especially retinopathy and nephropathy), according to the Eighth Joint National Committee (JNC 8) therapy should be initiated when the patient has a blood pressure at or above 140/90 mm Hg. Other organizations recommend the lower goal of 130/80 in clients with DM. Option 2: Owing to the beneficial effects of reducing albuminuria and glomerular pressure, angiotensin- converting enzyme (ACE) inhibitors are the drugs of choice in clients with DM with hypertension. Option 3: ACE inhibitors should be initiated in patients with diabetes and an elevated blood pressure and are recommended in normotensive patients with albuminuria. Option 4: Depending on the guidelines, therapy should be initiated when blood pressure reaches levels equal to or 10 mm Hg less than conventional therapeutic guidelines. [Page reference: 932] ● Course Topic: Endocrine and Metabolic Problems ● Area of Practice(s): Adult-Gerontology Primary Care; Family Practice ● APN Knowledge Area(s): Pharmacologic Therapy and Polypharmacy, Disease Management ● Testing Domain: Plan ● Cognitive Level: Analysis [Analyzing] Question 3. Dan, age 45, is obese and has type 2 diabetes. He has been having trouble getting his glycohemoglobin under control. He has heard that exenatide (Byetta) causes weight loss and wants to try it. What do you tell him? 1. “Let’s adjust your oral antidiabetic agents instead.” 2. “That’s a myth. People usually change their eating habits when taking this, and that’s what causes the weight loss.” 3. “With type 2 diabetes, you never want to be on injectable insulin.” 4. “Let’s try it. Your glycohemoglobin will be lowered and you may lose weight.” Rationales Option 1: Adjusting the client’s oral antidiabetic agents may not be as effective, but these drugs are less expensive. Option 2: Exenatide (Byetta) can cause weight loss in some individuals. Question 5. Which of the following is not a risk factor for diabetes mellitus type 2? 1. Body mass index (BMI) greater than 25. 2. History of gestational diabetes. 3. Caucasian race. 4. History of polycystic ovary syndrome (PCOS). Rationales Option 1: A BMI greater than 25 is a risk factor for diabetes mellitus type 2. Option 2: A history of gestational diabetes is associated with the development of diabetes mellitus type 2 later in life. Option 3: Caucasians are less likely than African Americans, Asian Americans, Latin Americans, and Native Americans to develop diabetes mellitus type 2. Option 4: Women diagnosed with PCOS are more likely to develop diabetes mellitus type 2. [Page reference: 923] ● Course Topic: Endocrine and Metabolic Problems ● Area of Practice(s): Adult-Gerontology Acute Care; Adult-Gerontology Primary Care; Family Practice ● APN Knowledge Area(s): Disease Management ● Testing Domain: Assess ● Cognitive Level: Knowledge [Remembering] Question 6. Bill, age 43, appears with a tender, ulcerated, exudative, papular lesion on his penis. It
Full content available after purchase or with an active subscription.
Related Products
Related Products
NR 511 Week 1 Assignment; National HIV Curriculum; Epidemiology of HIV.
NR 511 Week 1 Discussion and Response; Clinical Preparedness
NR 511 Week 1 Exam; CEA Pre-Clinical Diagnostic Exam
NR 511 Week 1 Exam; CEA Pre-Clinical Diagnostic Exam - Comprehensive Practice Questions -Answers
NR 511 Week 1 Exam; CEA Pre-Clinical Diagnostic Exam - Practice Questions (150 Questions-Answers)
NR 511 Week 1 Exam; CEA Pre-Clinical Diagnostic Exam - Practice Test
NR 511 Week 1 Quiz - All Correct
NR 511 Week 1 Quiz - Correct Answers
NR 511 Week 2 iHuman Virtual Patient Encounter - Kaylee Hales
NR 511 Week 2 iHuman Virtual Patient Encounter - Kecia Young.
NR 511 Week 2 iHuman Virtual Patient Encounter Attempt 2484649 - Gemma Jones
NR 511 Week 2 iHuman Virtual Patient Encounter Attempt 2551363 - Kecia Young
NR 511 Week 2 iHuman Virtual Patient Encounter Attempt 2619857 - Olive Chaney
NR 511 Week 2 iHuman Virtual Patient Encounter Attempt 3073958 - Olive Chaney
NR 511 Week 2 iHuman Virtual Patient Encounter Attempt 3659465 - Krista Hampton
NR 511 Week 2 iHuman Virtual Patient Encounter Attempt 3776521 - Kaylee Hales
NR 511 Week 2 iHuman Virtual Patient Encounter Attempt 3786583 - Kaylee Hales.
NR 511 Week 2 Reflection; Vaccination Strategies Among Young Adults Guided by Healthy People 2030 Objectives
NR 511 Week 3 Open Forum; SNAPPS Presentation
NR 511 Week 3 Quiz - Correct Answers
NR 511 Week 3 SNAPPS ORAL Presentation
NR 511 Week 3 SNAPPS Presentation
NR 511 Week 3 SNAPPS Written Assignment
NR 511 Week 3 SNAPPS Written Assignment Template; Dizziness & Giddiness
NR 511 Week 3 SNAPPS Written Assignment; Clinical Prediction Rules for Acute Pharyngitis
NR 511 Week 3 SNAPPS Written Assignment; H2 Antagonists vs. PPIs in GERD Management
NR 511 Week 3 SNAPPS Written Assignment; Interstitial Cystitis
NR 511 Week 3 SNAPPS Written Assignment; Managing Low Libido & Mood in Menopause
NR 511 Week 4 Clinical Virtual Interactive Student Evaluation (VISE) Assignment (Due by the end of Week 5)
NR 511 Week 4 iHuman Case Study Performance Overview - Victoria Lewis
NR 511 Week 4 Midterm Exam
NR 511 Week 4 Midterm Exam Solutions
NR 511 Week 4 Midterm Study Guide
NR 511 Week 4 Midterm Study Guide - Syllabus Content
NR 511 Week 5 Discussion & Responses; Preventative Care Screenings
NR 511 Week 5 Discussion Post and Responses
NR 511 Week 5 Discussion; Preventative Care Screenings.....
NR 511 Week 5 iHuman Case - Deborah Arnaudin
NR 511 Week 5 iHuman Virtual Patient Encounter Attempt 2517019 - Vijay Rao
NR 511 Week 5 iHuman Virtual Patient Encounter Attempt 2559832 - Nolan Young
NR 511 Week 5 iHuman Virtual Patient Encounter Attempt 2632375 - Luca Alaniz
NR 511 Week 5 iHuman Virtual Patient Encounter Attempt 2792702 - Marta Hernandez
NR 511 Week 5 iHuman Virtual Patient Encounter Attempt 3689162 - Deborah Arnaudin
NR 511 Week 5 iHuman Virtual Patient Encounter Attempt 3693474 - Deborah Arnaudin
NR 511 Week 5 iHuman Virtual Patient Encounter Attempt 3723068 - Dorothy Jones
NR 511 Week 5 iHuman Virtual Patient Encounter Attempt 3741013 - Dorothy Jones
NR 511 Week 5 iHuman Virtual Patient Encounter Attempt 3748568 - Dorothy Jones
NR 511 Week 5 iHuman Virtual Patient Encounter Attempt 3751980 - Dorothy Jones
NR 511 Week 5 iHuman Virtual Patient Encounter Attempt 3752448 - Dorothy Jones
NR 511 Week 5 iHuman Virtual Patient Encounter Reflection - Abdominal Assessment..
NR 511 Week 5 iHuman Virtual Patient Encounter; Abdominal Pain in 54-Year-Old Female - Dorothy Jones
NR 511 Week 5 Quiz - 10 out of 10 Point
NR 511 Week 5 Quiz - 10 out of 10 Points
NR 511 Week 5 Quiz - 10 out of 10 Points.
NR 511 Week 6 Assignment; National HIV Curriculum - HIV Screening Recommendations
NR 511 Week 6 Assignment; National HIV Curriculum - Linkage to HIV care
NR 511 Week 6 Discussion; Sexually Transmitted Disease..
NR 511 Week 6 Quiz - 10 out of 10 Points.
NR 511 Week 6 Quiz - 10 out of 10 Point
NR 511 Week 6 Quiz - 10 out of 10 Points
NR 511 Week 7 Faculty Tip Sheet - Musculoskeletal
NR 511 Week 7 iHuman Virtual Patient Encounter Attempt 3776523 - Virginia Lee
NR 511 Week 7 iHuman Virtual Patient Encounter Attempt 3812567 - Virginia Lee
NR 511 Week 7 iHuman Virtual Patient Encounter Attempt 3819281 - Virginia Lee
NR 511 Week 7 Quiz - All Correct Answers
NR 511 Week 8 Final Exam Practice - Gastrointestinal Disorders
NR 511 Week 8 Final Exam; 100 Questions-Answers
NR 511 Week 8 Final Exam.
Academic Use Notice: This resource is provided strictly as study support material to help students review concepts, understand topic structure, and prepare their own original academic work responsibly. It is not intended to be submitted directly as a student's own work.